CONSUMER EXPERIENCE

Understanding finished-product experience.

veMico has conducted open-label, uncontrolled evaluations of Y Collection products to learn how consumers describe their experiences. These support formulation development but do not establish clinical efficacy or the independent contribution of VMK223.

Request technical information

01 · Y GUT sensitive Y GUT sensitive product pouches on a warm, softly lit commercial set; illustrative packaging representation

Open-label consumer evaluation of gastrointestinal experience

30 daysOpen-labelNon-randomised80 received product62 completed surveys18–65 years

The evaluation recruited adults reporting three or more gastrointestinal symptoms. Participants used Y GUT sensitive, a powder containing 200 mg/day VMK223 and 1.5 g/day VMKBGOS (a prebiotic galactooligosaccharide preparation), while maintaining their usual diets and lifestyles.

Perceived gut function82%Reported improvement

Overall symptoms91%Reported overall symptom improvement

Product experience84%Reported they would recommend the product

78%Reported constipation improvement

75%Reported discomfort/pain improvement

70%Reported bloating improvement

Study context. Findings relate to the complete VMK223 + VMKBGOS formulation, not VMK223 alone. The study had no placebo group or formal statistical testing. Some participants reported gas, bloating or discomfort during the evaluation. The report was based on voluntary online questionnaires rather than a comprehensive safety assessment.

Source: veMico, Y GUT sensitive Consumer Study Technical Report (company data on file).

02 · Y SKIN Y SKIN jar and carton on a blush and lavender commercial set; illustrative packaging representation

Open-label consumer evaluation of perceived skin appearance

30 daysOpen-labelNon-randomised79 received product73 completed surveys39–65 years

Adults who regularly used skincare products evaluated Y SKIN capsules containing 500 mg/day VMK223. Participants maintained their usual skincare and lifestyle routines and reported their perceptions through pre- and post-evaluation surveys.

Overall skin perception84%Reported healthier, more radiant-looking skin

Texture and hydration77%Reported improvement

Wrinkles and/or acne-related concerns61%Reported improvement

81%Reported expectations met or exceeded

79%Reported they would recommend the product

73Completed-response dataset

Study context. These are subjective reports, not instrumentally measured skin outcomes. The study was uncontrolled, non-randomised and descriptive. No adverse effects were reported in the survey report, but the evaluation was not designed as a comprehensive safety study.

Source: veMico, Y SKIN Consumer Study Technical Report (company data on file).

How to read the percentages. Each technical report identifies completed-survey datasets of 62 and 73 people respectively; individual question-level denominators were not reported separately. Results are shown exactly as summary percentages reported by veMico, and should not be interpreted as percentages of all recipients or placebo-adjusted effects.

These evaluations were company-organised consumer surveys and should be distinguished from peer-reviewed randomised controlled trials. Any use of these outcomes in commercial communications requires market-specific regulatory assessment.